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Diabetic cardiomyopathy is a complication of type 2
diabetes, with known contributions of lifestyle
and genetics. We develop environmentally and
genetically driven in vitro models of the condition
using human-induced-pluripotent-stem-cell-derived
cardiomyocytes. First, we mimic diabetic clinical
chemistry to induce a phenotypic surrogate of
diabetic cardiomyopathy, observing structural and
functional disarray. Next, we consider genetic
effects by deriving cardiomyocytes from two dia-
betic patients with variable disease progression.
The cardiomyopathic phenotype is recapitulated in
the patient-specific cells basally, with a severity
dependent on their original clinical status. These
models are incorporated into successive levels of a
screening platform, identifying drugs that preserve
cardiomyocyte phenotype in vitro during diabetic
stress. In this work, we present a patient-specific
induced pluripotent stem cell (iPSC) model of a com-
plex metabolic condition, showing the power of this
technique for discovery and testing of therapeutic
strategies for a disease with ever-increasing clinical
significance.INTRODUCTION
The World Health Organization estimates that the lethal clinical
trajectory of type 2 diabetes mellitus (T2DM) will make it the sev-810 Cell Reports 9, 810–820, November 6, 2014 ª2014 The Authorsenth leading cause of death worldwide by 2030. Cardiovascular
disease is the primary cause of death in this group, with data
indicating that diabetes has a negative effect on cardiac muscle,
independent of concurrent vascular influences such as coronary
artery disease (Devereux et al., 2000). This condition is known as
diabetic cardiomyopathy (DCM), which progresses to dilated
cardiomyopathy and heart failure (Mandavia et al., 2013).
T2DM induces specific cellular and molecular changes in the
cardiomyocyte (CM), which lead to the pathology of these con-
ditions. For example, the majority of the ATP required by healthy
adult CMs is produced by fatty acid b-oxidation, with only a
minor contribution from glucose and lactate oxidation. During
nondiabetic cardiac disease and injury, CM metabolism reverts
to an immature, fetal profile, with increased reliance on glucose
oxidation (Lopaschuk and Jaswal, 2010). However, as a result of
myocardial insulin resistance, T2DM promotes fatty acid
b-oxidation in CMs, with pathological consequences (Heather
and Clarke, 2011). First, fatty acid b-oxidation produces less
ATP per O2 consumed, reducing myocardial efficiency (Lorenzo
et al., 2013). Second, toxic lipid metabolites such as ceramide
accumulate in the CM, a response that is exacerbated by hyper-
lipidemia. Lastly, these metabolic changes distort CM structure.
Mitochondrial dysfunction and reactive oxygen species (ROS)
production activate ROS-sensitive proteases, which cleave
myofilament proteins (Steinberg, 2013). Concurrently, oxida-
tion-dependent ER stress impairs protein maturation and pro-
motes degradation of newly synthesized proteins at the ER
(Minamino and Kitakaze, 2010). Proteolytic damage and inade-
quate protein production synergize, resulting in loss of sarco-
meric integrity. Together, these changes result in the clinical
symptoms of DCM.
Despite its profound clinical impact, there is no specific
treatment for DCM, and the complex etiology of the condition
makes drug screening problematic. Here, we aimed to develop
in vitro DCM models using human induced pluripotent stem
cell (iPSC)-derived CMs. These cells have been used in studies
of cardiac hypertrophy, arrhythmia, toxicology, and metabolism
(Carlson et al., 2013; Ma et al., 2011). Apart from the advantages
of using cells of human origin, harnessing iPSC technology
enables the generation of patient-specific models of disease.
We show that a surrogate DCM phenotype emerges in these
cells upon exposure to a prodiabetic environment and that
a similar phenotype is present in the absence of a diabetic stim-
ulus in two diabetic-patient-specific cell lines. We utilize both
of these models to establish a screening platform for the identi-
fication of small molecules that rescue CM function in vitro
during diabetic stress.
RESULTS
Metabolic Manipulation Alters Maturation Status
of iPSC-CMs
Before investigating diabetes-dependent changes in CM func-
tionality, we considered how to best use iPSC-CMs in our
study. DCM is a disease of adult CMs, which have defined
structural, molecular, and metabolic characteristics. Human
iPSC-CMs more closely resemble neonatal CMs, with a degree
of flexibility that can change cellular phenotype, depending on
the experimental conditions (Carlson et al., 2013). We hypoth-
esized that promoting adult patterns of metabolic activity
would give a more-suitable baseline on which to model the
response of CMs to diabetic conditions. To test the effect of
controlling cellular metabolism, CMs were exposed to either
standard manufacturer’s maintenance medium (SM) or matura-
tion medium (containing insulin and fatty acids, but no glucose)
for 3 days after plating. In maturation medium (MM), ATP syn-
thesis must be maintained by fatty acid b-oxidation, mimicking
the metabolic substrate usage of the adult ventricular CM.
As changes to cellular metabolism have been associated
with promotion of cellular maturity (Carlson et al., 2013), we
determined the structural, molecular, and electrophysiological
impact of this manipulation. First, we quantified the striated
pattern of immunofluorescent (IF) a-actinin staining (CM score)
as a correlate of the development of CM subcellular structure
and sarcomeric integrity. Culturing iPSC-CMS in MM for
3 days increased CM score (Figures 1A and 1B), relative to
cells grown in SM. Sarcomere length also increased (Fig-
ure 1C). These changes in subcellular structure were accom-
panied by altered electrophysiological properties (Figure 1D).
The upstroke velocity and duration of the action potential
were increased in cells grown in MM (Figures 1E and 1F), char-
acteristics associated with CM maturation (Yang et al., 2014).
The total and live cell count did not change over the 3-day cul-
ture period (Figures 1G and 1H), and there was no increase in
the proportion of dead cells (Figure 1I), excluding the possibil-
ity that MM selects against an immature cell population. Next,
we analyzed gene expression patterns before and after the 3-
day period in MM (Figure 1J). Genes annotated by the striated
muscle contraction gene ontology term were enriched over
time (Figure 1J), including myosin light chains: MYL2; MYL3;
and MYL4. Genes involved in regulation of sarcoplasmic retic-Culum (SR) calcium content (SERCA2A and PLN) were also
increased, whereas expression of fetally enriched genes
(NPPA, NPPB, and ACTA1) was repressed. Together, these re-
sults suggest that MM shifts the gene-expression profile of
iPSC-CMs toward an adult-like pattern (Yang et al., 2014).
Interestingly, expression of voltage-gated sodium channel sub-
units SCN5a (pore-forming subunit) and SCN2B (regulatory
subunit) also increased upon culture in MM (Figure 1K). To
test whether this was associated with a change in the proper-
ties of the CM sodium current, we performed patch clamp ex-
periments. Consistent with a 2-fold increase in expression of
the SCN5a subunit (Figure 1K), there was a strong statistical
trend toward doubling of peak sodium current, measured by
whole-cell voltage clamp and normalized to cell capacitance
(Figure 1L; p = 0.055) following 3 days culture in MM. Addition-
ally, we observed an increase in the slope of the sodium chan-
nel activation curve between 60 and 30 mV, consistent with
an increase in cellular excitability over this maturation period
(Figure 1M). Together, these data suggest that culture in MM
induces expression and sarcolemmal integration of functional
voltage-gated sodium channels. As these channels generate
the rapid depolarization phase of the CM action potential,
these data are in agreement with the increased action potential
upstroke velocity shown in Figure 1F.
Taken as a whole, these data show structural, molecular, and
electrophysiological characteristics associated with maturing
CMs became more pronounced following incubation in MM.
Although the cells do not attain a full adult phenotype, metabolic
dependence on fatty acid b-oxidation recapitulates cellular
activities prominent in more mature cells, giving a more-appro-
priate baseline for DCM modeling.
Exposure to a Diabetogenic Environment Induces a
Phenotypic Surrogate of Diabetic Cardiomyopathy
Clinically, diabetic patients show hyperglycemia, hyperlipid-
emia, and altered plasma levels of neurohormonal and inflam-
matory mediators (Mandavia et al., 2013). We hypothesized
that exposure of human-iPSC-derived CMs to a diabetic-like
environment would promote cell-autonomous features similar
to DCM. During the 3-day period in MM, CMs are exposed
to persistent insulin signaling in the absence of glucose,
forcing adaptation to fatty acids as a carbon source. We hy-
pothesized that reintroduction of glucose following cellular
maturation in MM (Figure S1A) would mimic the conditions
found in diabetes: glucose excess despite a metabolic reli-
ance on fatty acids. To quantify the cellular response, brain
natriuretic peptide (BNP) release was measured. Addition of
glucose dose-dependently increased BNP secretion over a
2 day culture period (Figure 2A). As T2DM is diagnosed
when fasting plasma glucose concentration exceeds 7 mM
and 10 mM glucose-induced maximal BNP release, this con-
centration was used for the continuation of our study. Next,
we tested whether addition of known hormonal mediators of
diabetes, endothelin 1 (ET-1) and cortisol, enhanced BNP
production. Maximal BNP secretion was consistently pro-
duced by culture of CMs in a diabetic milieu (DM) of glucose
(10 mM), ET-1 (10 nM), and cortisol (1 mM) together (Figure 2B).
Microarray analysis confirmed reversion of DM-treated CMsell Reports 9, 810–820, November 6, 2014 ª2014 The Authors 811
Figure 1. Metabolic Manipulation of iPSC-
CMs Enhances Characteristics Associated
with Maturing CMs
(A) Representative image of SM/MM-treated cells.
a-actinin (green); DAPI (blue); scale bar, 50 mm.
(B) CM score following exposure to standard me-
dium (SM) or maturation medium (MM) for 3 days.
(C) Sarcomere length in CM exposed to SM or
MM for 3 days. a.u., arbitrary units.
(D) Representative spontaneous action potential in
CMs exposed to SM or MM for 3 days. CMs were
loaded with a voltage-sensitive dye and change in
fluorescence intensity monitored over time.
(E) Action potential duration at 90% repolarization
(APD90) calculated from traces of voltage-sensi-
tive dye fluorescence intensity in CMs exposed to
SM or MM for 3 days.
(F) Action potential upstroke velocity calculated
from traces as in (A) of CMs treated with SM or MM
for 3 days.
(G) Total number of CMs after 0, 1, 2, or 3 days
culture in MM.
(H) Percent of live cells measured by calcein-AM
uptake in CMs exposed to 0, 1, 2, or 3 days of
culture in MM.
(I) Percent of dead cells measured by ethidium-
homodimer-1 uptake in CMs exposed to 0, 1, 2, or
3 days of culture inMM. The higher percent of dead
cells at day 0 reflects nonadherent cells remaining
after plating.
(J) mRNA expression of TMOD1, TNNI1, TNNI3,
MYL2, MYL3, MYL4, and MYBPC3 measured by
microarray in cells before (day 0) and after (day 3)
maturation in MM.
(K) mRNA expression of SCN5a and SCN5b
measured by microarray in cells before (day 0) and
after (day 3) maturation in MM.
(L) Peak whole-cell sodium current measured
at 40 mV and normalized to cell capacitance to
control for cell size in day 0 and day 3 CMs.
(M) Slope of the sodium channel activation curve
measured between 60 and 30 mV in day 0 and
day 3 CMs.
Data represent the mean ± SEM of at least three
experiments. *p < 0.05, **p < 0.01, and ***p < 0.001.to a pattern of gene expression associated with hypertrophic
stress (Taegtmeyer et al., 2010). The hypertrophic markers
NPPA, NPPB, ACTA1, and MYH7 were elevated at the
mRNA level (Figure S1B) whereas MYH6 was diminished.
mRNA levels of the chamber-specific markers MYL7 (atrial),
MYL2 (ventricular), and IRX4 (ventricular) were unchanged
(Figure S1B), verifying that the extent and nature of cellular
differentiation was not altered by DM treatment. Confirming
the prohypertrophic and pathological effect of the diabetic
milieu, CMs treated with DM released greater amounts of
the cardiac pathological stress proteins troponin I and FABP3
(Figures S1C and S1D).812 Cell Reports 9, 810–820, November 6, 2014 ª2014 The AuthorsWhen DM-treated CMs were examined
by IF, we observed increases in cellular
(Figures 2C and 2E) and nuclear surface
area (Figures 2C and S1E), definitiveconfirmation of hypertrophy. Interestingly, a loss of sarcomeric
integrity was also apparent. The regular striped pattern of
a-actinin staining became diffuse (Figure 2C). Consequently,
CM score was diminished after 2 days exposure to DM (Fig-
ure 2D). Next, we tested whether the response to DM persisted
beyond the duration of the stimulus. After 48 hr exposure to DM,
DM was replaced with MM for a further 48 hr and CM score,
nuclear area, and BNP release quantified at both 48 and 96 hr
posttreatment. Removal of DM did not permit CM score (Fig-
ure S1F) or nuclear area (Figure S1G) to return to the level of
the untreated control. Indeed, values for CM score and nuclear
area after stimulus washout were similar to those measured
Figure 2. A Diabetogenic Extracellular Environ-
ment Induces CM Hypertrophy and Loss of
Sarcomeric Integrity
(A) Dose response for glucose-stimulated BNP
secretion. BNP in the culture supernatant was quan-
tified after 2 days treatment of CMs with 0.3–30 mM
glucose in MM.
(B) BNP secretion after 2 days treatment of CMs with
MM plus glucose (10 mM), ET-1 (10 nM), and cortisol
(1 mM) singly or in combination.
(C) IF images of CMs grown in MM or diabetic medium
(DM: 10 mM glucose, 10 nM ET-1, and 1 mM cortisol)
for 2 days. a-actinin (green); DAPI (blue); scale bar,
50 mm. Top panels: MM-treated cells. Bottom panels:
DM-treated cells. The area within the white square is
shown at a higher magnification on the right; scale bar,
20 mm.
(D) Quantification of CM score in CMs exposed to MM
or DM for 2 days as in (C).
(E) Cell surface area of CMs treated as in (C).
(F) Transmission electron micrographs of CMs
cultured in MM or DM for 2 days (scale bar, 2 mm).
Black arrows identify z discs; mt, mitochondria; n,
nucleus; z, z body; zd, z disc.
(G) Calcium transient frequency in CMs exposed to
MM or DM. CMs were loaded with calcium 5 and
fluorescence intensity monitored over 30 s.
(H) CM beat amplitude in cells as in (C) measured by
impedance monitoring.
(I) Beat-rate irregularity in CMs as in (C). Cellular
impedance was monitored and the interval between
CM beats measured. Beat-rate irregularity, the coef-
ficient of variation of the beat interval.
Data represent the mean ± SEM of at least three ex-
periments. *p < 0.05, **p < 0.01, and ***p < 0.001. See
also Figures S1 and S2.
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with our standard 48 hr DM treatment (Figures S1F and S1G).
Conversely, BNP release fell to negligible levels following DM
removal (Figure S1H), similar to that of untreated control CMs.
To confirm that the structural changes we observed by IF were
truly a reflection of sarcomeric disorder, we examined CMs at
the ultrastructural level (Figure 2F). Transmission electron
microscopy of CMs cultured in MM for 48 hr confirmed a regular
parallel arrangement of myofilaments within sarcomeres and
prominent z discs. Although isolated areas of well-organized
CM structure were identifiable in DM-treated CMs, the majority
of cells exhibited myofilament disarray and a lack of pronounced
z discs. Instead, we observed the emergence of punctate
electron dense structures known as z bodies, which appear
when the linear structure of the z disc is absent. These features
are similar to those observed in failing human heart specimens
and genetic cardiomyopathies (Sun et al., 2012), confirming
that the changes in the pattern of sarcomere staining do reflect
structural abnormality.
As loss of sarcomeric integrity disturbs the close physical
coupling between calcium release units and contractile proteins
(Bers, 2008), we investigated the functional consequences of
sarcomeric disarray. In CMs exposed to DM, the frequency of
systolic calcium transients decreased (Figure 2G). Furthermore,
impedance-based monitoring (Abassi et al., 2012) revealed that
the amplitude of CM beats was reduced in DM-treated cells
(Figure 2H). Beat rate irregularity, a measure of the variability
of the interval between beats, was increased (Figure 2I). These
data show a functional impact of DM treatment, with fewer
calcium transients producing poorly coordinated, weaker, and
irregular CM beats.
In Vitro Induction of DCM Promotes Lipid Accumulation
and Peroxidation
Diabetic CMs display a number of additional specific features
that contribute to the pathogenesis of structural disarray, such
as lipid accumulation and oxidative stress. To test whether these
processes were active in our system, we estimated intracellular
lipid accumulation. Following 2 days exposure to DM, lipid accu-
mulated in the cytosol (Figures S2A and S2B). Quantification of
peroxidation levels revealed that the deposited lipid was exten-
sively oxidized (Figures S2C and S2D), indicating that, under
DM-treated conditions, CMs are exposed to oxidative stress.
To gain a holistic view of the molecular changes that may drive
the observed phenotypes, we analyzed gene-expression profiles
in DM-treated CMs and interpreted the data using gene set
enrichment analysis (GSEA). Sixty-four gene sets were positively
enriched in the diabetic condition, whereas 140 gene sets dis-
played diminished expression (Table S1). We generated an
enrichment map of the GSEA, clustering and categorizing signif-
icantly altered gene sets (Figure S2E). We identified positive
enrichment of major clusters related to cellular metabolism:
genes involved in the tricarboxylic acid (TCA) cycle (e.g., pyru-
vate dehydrogenase kinase), mitochondrial electron transport
chain (e.g., ATP synthase subunits and cytochrome C), and
glucose metabolism (e.g., enolase) were upregulated. Other en-
riched categories included cell adhesion (e.g., integrins) and
extracellular matrix deposition (e.g., collagens). The expression
of several gene clusters was diminished after DM exposure,814 Cell Reports 9, 810–820, November 6, 2014 ª2014 The Authorsincluding genes involved in the cell cycle (e.g., DNA replication
proteins), protein translation (e.g., ribosomal proteins and eu-
karyotic initiation factors), and the unfolded protein/ER stress
response (e.g., ATF4 and CHOP10). Altogether, in the DM condi-
tion, there is a generalized increase in metabolic gene expres-
sion and suppression of genes controlling protein synthesis
and the cellular response to dysfunctional protein production.
Despite an excess of metabolic intermediates and activated
metabolic pathways, the ability of the cell to produce new pro-
teins appears to be compromised.
The results presented suggest that CMs exposed to a diabetic
milieu of glucose, ET-1, and cortisol recapitulate a diabetic
cardiomyopathic phenotype in vitro. DM-treated cells show
disorganized sarcomeres, altered calcium transients, cellular
hypertrophy, lipid intracellular accumulation, oxidative stress,
and deficits in the expression of genes controlling protein pro-
duction. The presence of multiple facets of the DCM cellular
phenotype in our model suggests that the changes we observe
are not simply a result of cellular dedifferentiation but transition
to a disease-like state.
CMs Derived from Diabetic-Patient-Specific iPSCs
Show a Cardiomyopathic Phenotype in the Absence
of a Diabetic Stimulus
We next wished to examine whether the in vitro phenotype of
our model is similar to that of diabetic patients. Considering
the difficulty of obtaining adult human cardiac material, we
tested whether iPSC technology could be harnessed to create
diabetic-patient-specific CM models. Using iPSC-CMs derived
from different patients, we could study the variable penetrance
of preexisting genetic and/or retained epigenetic factors on
CM phenotype. We categorized diabetic patients with different
clinical histories using stringent inclusion and exclusion criteria.
To best test the likelihood that genetic/epigenetic predisposi-
tion would affect phenotype, two diabetic extreme phenotypes
were selected: fast progression (FP), with development of
cardiovascular disease (CVD) within 5 years of initial diabetes
diagnosis, and slow progression (SP), with no CVD despite
15 years T2DM (Table S2). Dermal fibroblasts from these
patients were retrovirally reprogrammed to pluripotency with
OCT4, SOX2, KLF4, and c-MYC. The iPSCs generated were
karyotypically normal (Figure S3A) and could be induced to
differentiate into embryoid bodies that express markers of the
three germ layers (Table S3). FP and SP CMs were derived
from iPSCs using identical standard cardiogenic methods
(Ma et al., 2011). Both FP and SP cultures were spontaneously
contractile, with greater than 90% of the cells cTnT positive.
Next, we characterized CMs as above. When cultured in MM
(+insulin, +fatty acids, and glucose) in the absence of diabetic
stress, CM score was lower in SP and FP CMs than standard
CMs, indicating sarcomeric disarray (Figures 3B and 3C).
Furthermore, the frequency of calcium transients was reduced
in the FP cells (Figure 3D) whereas beat rate irregularity was
increased (Figure 3E). FP CMs also accumulated more intracel-
lular peroxidized lipid (Figures 3F, 3G, and S3B), indicative of
oxidative stress. These findings are similar to those observed
in standard CMs on exposure to DM. Interestingly, in the
absence of the diabetic milieu, SP CMs had an intermediate
Figure 3. Diabetic-Patient-Specific CMs
Exhibit a Diabeto-Mimetic Phenotype in
the Absence of Cellular Stimulation
(A) Cartoon to show the three types of CM. CM
were derived from standard iPSC (S, green), slow-
progressing diabetic iPSC (SP, blue), and fast-
progressing diabetic iPSC (FP, red).
(B) IF images of standard, SP, and FP CMs.
a-actinin (green) and DAPI (blue); scale bar, 30 mm.
(C) CM score of standard, SP, and FP CMs
cultured in MM for 2 days.
(D) Calcium-transient frequency in standard, SP,
and FP CMs exposed to MM for 2 days.
(E) Beat-rate irregularity in S, SP, and FP CMs.
(F) Quantification of lipid accumulation by nile red
staining in standard, SP, and FP CMs cultured in
MM for 2 days.
(G) Quantification of lipid peroxidation in standard,
SP, and FP CMs cultured in MM for 2 days.
(H) Enrichment map to represent gene sets en-
riched following mRNA sequencing of FP and SP
CMs to compare gene expression between the
two cell types. mRNA sequencing was performed
on duplicate samples. Each node represents a
significantly enriched gene set; positively enriched
sets in the FP CMs are shown in red, negatively
enriched sets in the FP CMs are in blue. Node size
is proportional to the total number of genes in each
set, and edge thickness represents the number of
overlapping genes between sets. Groups of func-
tionally related gene sets are circled and labeled.
Data represent the mean ± SEM of at least three
experiments. *p < 0.05, **p < 0.01, and ***p <
0.001. See also Figures S3 and S4.phenotype, with fewer striations per cell but no significant
reduction in the frequency of calcium transients or beat rate ir-
regularity (Figures 3B–3E). Similarly, levels of intracellular lipid
and the extent of lipid peroxidation were not increased in
SP CMs over standard CMs (Figures 3F, 3G, and S3B). This
suggests that SP CMs had a milder loss of sarcomeric integrity,
without progression to overt lipid-induced toxicity. Upon expo-
sure to DM, both SP and FP CMs further reduced CM score
(Figure S3C), increased BNP release (Figure S3D), and
increased the accumulation of intracellular lipid and lipid
peroxidation (Figures S3E and S3F).
Taken together, these data indicate that a diabetic pheno-
type can be recapitulated in MM in FP CMs. In concordance
with the milder disease phenotype of the patient of origin, SP
CMs show only partial dysfunction in the absence of diabetic
stress. The observation that patient-specific cells display a
basal DCM phenotype that corresponds to the clinical status
of the original donor is revealing. To gain a deeper understand-
ing of the molecular changes that may underlie the differences
between SP and FP cells, we compared gene-expression
profiles between the two cell types using RNA sequencing.
An enrichment map of the results (Figure 3H) showed that,Cell Reports 9, 810–820,similar to standard CMs exposed to
DM (Figure S2E), expression of genes
related to DNA synthesis and mitosiswas lower in the FP CMs. Furthermore, genes involved in mus-
cle contraction and the TCA cycle were negatively enriched
in the FP cells. Positively enriched genes included the gluco-
corticoid receptor and calcineurin-nuclear factor of activated
T cells (NFAT)-signaling pathways. This result is intriguing,
given that cortisol (a glucocorticoid receptor agonist) is a
component of DM and that the calcium-calcineurin-NFAT
pathway has well-described roles in ET-1-dependent hypertro-
phic CM remodeling (Drawnel et al., 2013).
High-Content Phenotypic Screening Identifies
Small Molecules that Can Prevent Development
of DCM In Vitro
Having established environmental and patient-specific models
of DCM with linked phenotypes, we developed a screening
assay to identify potential protective drugs. We conducted our
primary screen on DM-treated cells, taking advantage of this
rapid model. To this end, we quantified several screenable
endpoints, CM score, nuclear area, and BNP production, in
DM-treated cells exposed to a library of small molecules with
annotated mechanisms of action (Figure 4A). To establish the
minimal stimulus necessary to mimic DCM in our system, thusNovember 6, 2014 ª2014 The Authors 815
Figure 4. Phenotypic Screening for Small
Molecules that Prevent Development of the
DCM Phenotype
(A) Cartoon to represent the assay to measure BNP
production, CM score, and nuclear area.
(B) CM score of CMs exposed to MM/mDM/BM
for 2 days. BM, DM + mifepristone (10 mM) and
bosentan (100 mM).
(C) BNP secretion into the culture supernatant of
CMs treated as in (B).
(D) Nuclear area from IF images of CMs treated as
in (B).
(E) Measurement of the number of DAPI+ nuclei
per imaged region of CMs treated as in (B).
(F) Pie chart to show the functional categories
of positive compounds identified in the primary
screen. Compounds were categorized according
to their primary mode of action, and examples of
the chemical structure of selected molecules from
each category are shown.
(G) Positive compounds from the primary screen
were tested at 0.1, 0.3, 1, and 10 mM and CM
score quantified. Six representative compounds
with dose-dependent effects on CM score and
six representative compounds with non-dose-
dependent effects on CM score are shown.
Measurements were performed in duplicate.
Data represent the mean ± SEM of at least
three experiments. ***p < 0.001. See also Figures
S5 and S6.increasing the window for drug-induced protective effects, we
reduced the concentration of the three cellular stressors. We
observed a similar pattern of phenotypes using the modified
DM (mDM) to that produced with the original conditions: CM
score declined (Figure 4B); BNP secretion increased (Figure 4C);816 Cell Reports 9, 810–820, November 6, 2014 ª2014 The Authorsnuclear area increased (Figure 4D); and
peroxidized lipid accumulated (Figures
S4A and S4B). There was no change in
cell number (Figure 4E). Subsequently,
mDM was our negative control for
assessing drug effectiveness for the pre-
vention of dysfunction. To establish a pos-
itive control, we preincubated CMs with
mifepristone to inhibit the glucocorticoid
receptor and bosentan to inhibit both
ETA and ETB receptors. A combination
of 10 mM mifepristone and 100 mM
bosentan (BM) effectively prevented onset
of the diabetic phenotype (Figures 4B–
4E). To determine assay robustness, we
analyzed the effect of mDM and BM
over multiple plates and experimental
runs and saw consistent responses (Fig-
ures S4C and S4D). DM-treated CMs
were exposed to a library of 480 com-
pounds and CM score, nuclear area, and
BNP secretion quantified after 2 days of
treatment. From the initial screen, we
used p value distribution analysis (Prum-mer, 2012) and identified 47 compounds that increase CM score,
while decreasing BNP secretion and nuclear area (Figures S4E
and S4F). Many of the positive compounds targeted proteins
involved in calcium homeostasis (Figure 4F), including inhibitors
of voltage-gated calcium channels (e.g., fluspirilene), molecules
that deplete intracellular calcium stores (e.g., thapsigargin), and
inhibitors of calcium-regulated proteins such as calmodulin
(e.g., W7). We also identified sodium and potassium channel
blockers (e.g., phenamil and penitrem A), which reduce the fre-
quency of CM calcium transients. Other chemical classes were
multikinase inhibitors (e.g., H89 and K252a), PDE5 inhibitors
(e.g., MY-5445 and MCBQ), and protein synthesis inhibitors
(e.g., lycorine and cyclohexamide). Next, to confirm efficacy
and dose-dependency of response, we tested a panel of the pri-
mary hits in a dose-response assay. Twenty-eight compounds
produced dose-dependent improvements in the disease param-
eters. Examples for CM score are shown in (Figure 4G). Trends
for BNP production and nuclear area were similar (Figures S5A
and S5B).
As shown in Figures S2B and S2D, DM treatment induces
accumulation of intracellular peroxidized lipid and in iPSC-
CMs, two of the hallmarks of DCM. We selected a variety of
the confirmed hits from the screen and tested whether these
molecules also prevented mDM-dependent lipid effects. BM
(bosentan and mifepristone), fluspirilene, lycorine, and H89 pre-
vented mDM-induced lipid accumulation (Figure S5C) and lipid
peroxidation (Figure S5D), relative to the drugs alone. Thapsi-
gargin was without effect on lipid accumulation or lipid perox-
idation (Figures S5C and S5D). Next, we tested whether
drug-induced preservation of CM structure translated into
rescue of DM-induced functional deterioration by quantifying
the frequency of cellular calcium transients. Similarly to DM,
mDM reduced calcium transient frequency. As expected from
their involvement in intracellular calcium-handling mechanisms,
thapsigargin and fluspirilene dramatically reduced the basal fre-
quency of calcium transients (Figure S5F). BM, lycorine, and
H89 prevented the mDM-induced reduction in calcium transient
frequency (Figures S5E and S5F).
Compounds Selected by a High-Content
Phenotypic Screen Can Rescue the Phenotype
of Patient-Specific CMs
Thus far, we have identified compounds that can prevent
dysfunction in human CMs on exposure to the diabetic milieu,
an environmental inducer of DCM. However, are these com-
pounds able to improve the phenotype of patient-derived CMs,
which is induced without environmental manipulation? To begin,
we examined whether the positive control from our screening
assay (BM) could rescue the basal DCM phenotype. Intriguingly,
BM treatment increased CM score in both the SP and FP CMs
(Figure 5A), suggesting that signaling pathways engaged by
the ET and glucocorticoid receptors may be relevant to the
cellular pathology in these cells. Encouraged by the efficacy of
our positive control, we tested a subset of the small molecules
identified in our primary screen (Figure 5B). This subset included
thapsigargin, fluspirilene, H89, and lycorine, the effects of which
were extensively characterized above. For the SP CMs, 14 of the
18 compounds increased CM score beyond the baseline for
standard CMs (Figure 5C). In agreement with their more-severe
pathology, fewer compounds were efficacious in the FP CMs
(Figure 5D). Ten of the 18 compounds improved FP CM score
beyond the standard cell baseline. For both cell types, the
most-effective compounds were thapsigargin and fluspirilene.CDISCUSSION
Cardiovascular complications of T2DM are unfortunately a com-
mon and life-threatening occurrence. No specific drug treatment
exists to prevent diabetes-induced cardiac dysfunction, a com-
plex multifactorial condition that is distinguished by a unique set
of metabolic, structural, and molecular changes within the dia-
betic CM. Here, we developed an in vitro screening platform
for DCM, considering diabetic clinical chemistry and patient-
specific cell lines. By mimicking the diabetic extracellular milieu,
we created a surrogate phenotype of DCM. Suppression of this
phenotype was used as a screenable endpoint to identify small
molecules that prevent the development of cellular dysfunction.
Furthermore, we employed diabetic patient iPSCs and showed
not only a more-severe basal phenotype for patient-derived
CMs but also an ability to intervene and improve the phenotype
pharmacologically.
The use of glucose, ET-1, and cortisol as a prodiabetic stim-
ulus in this study is based on findings from diabetic patients
(Reynolds et al., 2010; Schneider et al., 2002). Exposure of
standard cells to DM following a period of glucose restriction
induced distortion of cellular structure, lipid accumulation,
oxidative stress, and hypertrophy—pathological hallmarks of
diabetic CMs. The same phenotype was later recapitulated in
the patient-derived CMs. In our primary screen, we identified
compounds that prevent induction of this phenotype and rescue
the associated functional consequences. Many of these sub-
stances have been mechanisms of action compatible with
what is known about the pathogenesis of diabetic cardiac
dysfunction. For example, molecules that prevent calcium entry
(fluspirilene and loperamide), reduce calcium in the SR (thapsi-
gargin), or inhibit calcium-regulated proteins (W7 and CAPE)
would limit the well-described pathological consequences of
elevated cytosolic calcium concentration. Furthermore, gene-
expression analysis revealed that the calcium-dependent
calcineurin-NFAT pathway is overrepresented in the FP-CMs.
Altogether, these data imply that deranged calcium cycling
and signaling contributes to DCM. Interestingly, several of these
molecules have been proposed as protective molecules in other
iPSC models of genetic cardiomyopathies (Moretti et al., 2013).
However, we also identified molecules with alternative mecha-
nisms of action. The protein synthesis inhibitors cyclohexamide
and lycorine were both identified in our primary screen, and our
analysis revealed that expression of genes involved in translation
and the unfolded protein response was changed in DM-treated
cells. Initially, the observation that inhibition of protein synthesis
can improve CM structure and function is counterintuitive, as
one would predict that inhibiting synthesis of new protein would
have a compounding negative effect. However, as we observed
in both DM-treated CMs and the patient-specific cells, diabetic
CMs experience lipotoxicity and lipid peroxidation. Both of these
features are associated with the activation of proteolytic en-
zymes, promotion of ER stress, and leak of calcium from the
SR (Ron and Walter, 2007). During ER stress, the unfolded pro-
tein response increases cellular resilience. Our expression data
showed that the expression of some members of this pathway
is lacking following exposure to DM. We postulate that using in-
hibitors of protein synthesis prevents accumulation of nascentell Reports 9, 810–820, November 6, 2014 ª2014 The Authors 817
Figure 5. The Phenotype of Patient-Specific
Diabetic CMs Can Be Rescued Pharmaco-
logically
(A) CM score of S, SP, and FP CMs cultured in MM
or BM for 2 days.
(B) The screening workflow from the primary
screen using standard cells to testing of positive
compounds on patient-specific cells.
(C) Ranked CM score in SP CMs exposed to 18
confirmed positive compounds. Compounds were
tested in duplicate at 10 mM. Blue line indicates
baseline CM score for the SP cells, and the green
line indicates the baseline CM score for the S cells.
(D) Ranked CM score in FP CMs exposed to 18
confirmed positive compounds. Compounds were
tested in duplicate at 10 mM. Red line indicates
baseline CM score for the FP cells, and the green
line indicates the baseline CM score for the S cells.
***p < 0.001.unfolded proteins and reduces load on the ER. This protects the
cell from further loss of sarcomeric integrity.
In vivo testing of the predictive power of our screening assay
remains an important future goal. However, such studies require
investment of time and resources, which render them impractical
for rapidly testing large numbers of compounds. Instead, we818 Cell Reports 9, 810–820, November 6, 2014 ª2014 The Authorstested our list of molecules on patient-
specific CMs. Previous patient-specific
iPSC-derived CM models have focused
on well-described single-gene cardiac
disorders (Moretti et al., 2013) or inherited
cardiomyopathies (Lan et al., 2013; Sun
et al., 2012). This reported iPSC-derived
model of a complex, polygenic cardiomy-
opathy shows the graded phenotype of
fast versus slow progression. These re-
sults raise the possibility that patient-spe-
cific models of complex disease could be
used to define disease subtypes, allowing
tailored drug treatments to be directed
to the group of patients most suitable
for their use. To definitively establish this
concept, it will be necessary to derive
and study CMs from a diverse set of
T2DM patients.
Intriguingly, the diabetic phenotype
emerges in the patient-specific cells in
the absence of a diabetic stimulus, sug-
gesting the cells are genetically/epi-
genetically predisposed for dysfunction.
Genome-wide association studies show
that multiple loci contribute to type 2 DM
complications, influencing individual dis-
ease risk (Bowden, 2002). An additional
layer of influence is provided by epige-
netics. Exposure of cells to periods of
hyperglycemia can modify the epige-
nome, with changes in DNA methylationpersistently altering gene expression and cellular responsive-
ness (Siebel et al., 2010). Moreover, epigenetic-dependent
‘‘metabolic memory’’ has been postulated to play a role in the
pathogenesis and progression of diabetic complications (Kato
and Natarajan, 2014). As iPSCs can retain amemory of their prior
differentiated state (Kim et al., 2011), it is plausible that CMs
differentiated from diabetic iPSCs may display a propensity
toward a diabetic phenotype upon differentiation, as a conse-
quence of epigenetically modified gene-expression patterns. In
agreement with a genetic/epigenetic hypothesis, we demon-
strated that the FP diabetic CMs displayed a more-extreme
phenotype than the SP cells, with a heightened predisposition
for dysfunction. The FP CMs were also more resistant to drug
treatment. These observations are consistent with the faster
clinical progression of the FP patient and suggest that the FP
patient may carry a more-severe combination of polymor-
phisms/modifications. Interestingly, neither FP nor SP CMs
released more BNP basally than standard CMs (Figure S3D),
although all cell types released BNP in response to DM. These
data are in concordance with the retention of structural disrup-
tion but fall in BNP release observed in standard cells after DM
removal (Figures S1F–S1H), suggesting that continued external
cellular stress is required to induce BNP production. In contrast,
structural disarray appears to be maintained by persistent
genetic/epigenetic alterations to intracellular pathways. Further
studies should address comparison of the genome and epige-
nome of the cells utilized here, in order to establish the origin
of the predisposition for cellular pathology.
In conclusion, we have established a paradigm in the search
for effective treatments for DCM. We show that, by using
iPSC-derived CMs, a disease with complex and multifactorial
etiology can be modeled in vitro and strategies for drug treat-
ment tested on different patient groups. This powerful platform
has the potential to discover new disease mechanisms and
target treatments to themost-appropriate individuals, enhancing
both specificity and efficacy.
EXPERIMENTAL PROCEDURES
Detailed descriptions of the experimental procedures are given in the
Supplemental Information.
CM Culture
CMs derived from CDI-MRB iPSCs (Cellular Dynamics International [CDI])
were thawed at 37C for 3 min and resuspended in plating medium (CDI).
We plated 35,000 viable cells per well on fibronectin-coated (Sigma) BD falcon
96-well imaging plates and rested at room temperature for 30 min. Cells were
incubated at 37C, 7%CO2 for 48 hr, and then platingmediumwas exchanged
for maturation medium (MM) for 72 hr. MM is Dulbecco’s modified Eagle’s
medium no glucose (GIBCO), 10mMHEPES, 2mML-carnitine, 5mMcreatine,
5 mM taurine, 1 mM nonessential amino acids (GIBCO), 13 insulin-transferrin-
selenium (Sigma-Aldrich), and linoleic-oleic acid (Sigma-Aldrich). After 72 hr,
MM was exchanged for DM (MM plus 10 mM glucose, 10 nM h-endothelin-
1, and 1 mM cortisol) or MM + vehicle control for a further 2 days.
Patient-Derived CMs
Human iPSC lines were derived from anonymized human skin biopsies
following full informed consent and approval by the Partners Healthcare
Human Research Committee (protocol number 2010-P-000122/1). iPSCs
were generated by retroviral reprogramming using OCT4, SOX2, KLF4, and
c-MYC and checked for pluripotency and normality of karyotype. iPSC lines
were transferred to CDI for differentiation into cardiomyocytes. Following
cardiomyocyte production, culture protocols were identical to those used for
the standard cardiomyocytes.
Imaging and Analysis
Imaging was performed using the PerkinElmer Operetta imaging systemwith a
203 objective. Per well, nine fields of view were captured and DAPI-stainedCnuclei identified with Harmony software. More than 2,500 cells were analyzed
per condition. Nuclear area was determined using the DAPI signal. To quantify
intracellular lipid/peroxidation, the intensity of fluorescence in the cell region
was measured. For the determination of CM score, a custom algorithm imple-
mented in the PerkinElmer image analysis software Acapella was developed.
Briefly, extended striation patterns were quantified using a pair of nonlinear
texture filters to enhance linear bright and dark features and subsequent
cross-correlation. From extracted features, such as the modulation amplitude
of the correlation image, a ‘‘CM score’’ was constructed as the proportion of
striated cells in the sample. For full details, see the Supplemental Information.
Statistical Analysis
Unless otherwise stated, all experiments were minimally performed in tripli-
cate. Results are presented as mean ± SEM. Statistical analyses were
performed in GraphPad Prism using the one-sample t test for two groups
and one-way ANOVA followed by Tukey analysis for two or more groups.
p < 0.05 was considered significant. Statistical analysis of the small molecule
screen is described in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The microarray data reported in this paper have been deposited to the NCBI
Gene Expression Omnibus and are available under accession number
GSE62203.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.09.055.
AUTHOR CONTRIBUTIONS
F.M.D., S.B., F.D., A.G., N.A., M.P., J.-C.H., A.K., L. Badi, T.K.-T., R.G., M.W.,
E.J., L. Bu, X.J., and J.B. performed/analyzed experiments, and F.M.D., S.B.,
J.B., B.J.H., K.R.C., K.K., M. Burcin, M. Boehringer, C.C., G.G., M.C.M., H.S.,
and R.I. designed experiments. F.M.D. and R.I. interpreted the data. F.M.D.,
K.K., M.P., and R.I. wrote the manuscript.
ACKNOWLEDGMENTS
This work was supported by the Roche Postdoctoral Fellowship Program
(to F.M.D., E.J., and S.B.). The authors would like to thank Inga Clausen and
Nicholas Flint for technical assistance, Prof. Adam Cohen for useful advice,
and Dr. Blake Anson and Dr. Ravi Jagasia for valuable comments on the
manuscript.
Received: May 14, 2014
Revised: August 27, 2014
Accepted: September 26, 2014
Published: October 30, 2014
REFERENCES
Abassi, Y.A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R.,
Bohlen, H., Ehlich, A., Kolossov, E., et al. (2012). Dynamic monitoring of
beating periodicity of stem cell-derived cardiomyocytes as a predictive tool
for preclinical safety assessment. Br. J. Pharmacol. 165, 1424–1441.
Bers, D.M. (2008). Calcium cycling and signaling in cardiac myocytes. Annu.
Rev. Physiol. 70, 23–49.
Bowden, D.W. (2002). Genetics of diabetes complications. Curr. Diab. Rep. 2,
191–200.
Carlson, C., Koonce, C., Aoyama, N., Einhorn, S., Fiene, S., Thompson, A.,
Swanson, B., Anson, B., and Kattman, S. (2013). Phenotypic screening with
human iPS cell-derived cardiomyocytes: HTS-compatible assays for interro-
gating cardiac hypertrophy. J. Biomol. Screen. 18, 1203–1211.ell Reports 9, 810–820, November 6, 2014 ª2014 The Authors 819
Devereux, R.B., Roman, M.J., Paranicas, M., O’Grady, M.J., Lee, E.T., Welty,
T.K., Fabsitz, R.R., Robbins, D., Rhoades, E.R., and Howard, B.V. (2000).
Impact of diabetes on cardiac structure and function: the strong heart study.
Circulation 101, 2271–2276.
Drawnel, F.M., Archer, C.R., and Roderick, H.L. (2013). The role of the para-
crine/autocrine mediator endothelin-1 in regulation of cardiac contractility
and growth. Br. J. Pharmacol. 168, 296–317.
Heather, L.C., and Clarke, K. (2011). Metabolism, hypoxia and the diabetic
heart. J. Mol. Cell. Cardiol. 50, 598–605.
Kato, M., and Natarajan, R. (2014). Diabetic nephropathy—emerging epige-
netic mechanisms. Nat. Rev. Nephrol. 10, 517–530.
Kim, K., Zhao, R., Doi, A., Ng, K., Unternaehrer, J., Cahan, P., Huo, H., Loh,
Y.-H., Aryee, M.J., Lensch, M.W., et al. (2011). Donor cell type can influence
the epigenome and differentiation potential of human induced pluripotent
stem cells. Nat. Biotechnol. 29, 1117–1119.
Lan, F., Lee, A.S., Liang, P., Sanchez-Freire, V., Nguyen, P.K., Wang, L., Han,
L., Yen, M., Wang, Y., Sun, N., et al. (2013). Abnormal calcium handling
properties underlie familial hypertrophic cardiomyopathy pathology in pa-
tient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101–113.
Lopaschuk, G.D., and Jaswal, J.S. (2010). Energy metabolic phenotype of the
cardiomyocyte during development, differentiation, and postnatal maturation.
J. Cardiovasc. Pharmacol. 56, 130–140.
Lorenzo, O., Ramı´rez, E., Picatoste, B., Egido, J., and Tun˜o´n, J. (2013).
Alteration of energy substrates and ROS production in diabetic cardiomyopa-
thy. Mediators Inflamm. 2013, 461967.
Ma, J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J.A., Kamp, T.J., Kolaja,
K.L., Swanson, B.J., and January, C.T. (2011). High purity human-induced
pluripotent stem cell-derived cardiomyocytes: electrophysiological properties
of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301,
H2006–H2017.
Mandavia, C.H., Aroor, A.R., Demarco, V.G., and Sowers, J.R. (2013).
Molecular and metabolic mechanisms of cardiac dysfunction in diabetes.
Life Sci. 92, 601–608.820 Cell Reports 9, 810–820, November 6, 2014 ª2014 The AuthorsMinamino, T., and Kitakaze, M. (2010). ER stress in cardiovascular disease.
J. Mol. Cell. Cardiol. 48, 1105–1110.
Moretti, A., Laugwitz, K.L., Dorn, T., Sinnecker, D., and Mummery, C. (2013).
Pluripotent stem cell models of human heart disease. Cold Spring Harb
Perspect Med 3. http://dx.doi.org/10.1101/cshperspect.a014027.
Prummer, M. (2012). Hypothesis testing in high-throughput screening for
drug discovery. J. Biomol. Screen. 17, 519–529.
Reynolds, R.M., Labad, J., Strachan, M.W.J., Braun, A., Fowkes, F.G.R., Lee,
A.J., Frier, B.M., Seckl, J.R., Walker, B.R., and Price, J.F.; Edinburgh Type 2
Diabetes Study (ET2DS) Investigators (2010). Elevated fasting plasma cortisol
is associated with ischemic heart disease and its risk factors in people with
type 2 diabetes: the Edinburgh type 2 diabetes study. J. Clin. Endocrinol.
Metab. 95, 1602–1608.
Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum
unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529.
Schneider, J.G., Tilly, N., Hierl, T., Sommer, U., Hamann, A., Dugi, K., Leidig-
Bruckner, G., and Kasperk, C. (2002). Elevated plasma endothelin-1 levels in
diabetes mellitus. Am. J. Hypertens. 15, 967–972.
Siebel, A.L., Fernandez, A.Z., and El-Osta, A. (2010). Glycemic memory
associated epigenetic changes. Biochem. Pharmacol. 80, 1853–1859.
Steinberg, S.F. (2013). Oxidative stress and sarcomeric proteins. Circ. Res.
112, 393–405.
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., Abilez, O.J., Navar-
rete, E.G., Hu, S., Wang, L., Lee, A., et al. (2012). Patient-specific induced
pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci.
Transl. Med. 4, 30ra47.
Taegtmeyer, H., Sen, S., and Vela, D. (2010). Return to the fetal gene program:
a suggestedmetabolic link to gene expression in the heart. Ann. N Y Acad. Sci.
1188, 191–198.
Yang, X., Pabon, L., and Murry, C.E. (2014). Engineering adolescence:
maturation of human pluripotent stem cell-derived cardiomyocytes. Circ.
Res. 114, 511–523.
